ReviewInfectious disease reports2022
Impact of COVID-19 on the Changing Patterns of Respiratory Syncytial Virus Infections.
Review in Infectious disease reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Anti-RSV drug screening and inhibition of RSV infection by lapatinib through the IL-17 pathway.Antimicrobial agents and chemotherapy · 2026Article
- Temporal trends in RSV-specific antibody seroprevalence among hosptalized children during the COVID-19 pandemic in Japan: a retrospective cross-sectional study.BMC infectious diseases · 2026Article
- Whole-Genome Phylodynamic Analysis of Respiratory Syncytial Virus-Maryland, USA, 2018-2024.Viruses · 2026Article
- Corrected and republished from: "Clinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021-2023 RSV outbreaks to investigate the immunity debt hypothesis".Microbiology spectrum · 2026Article
- Real-world impact of nirsevimab on the epidemiology and severity of pediatric respiratory syncytial virus infections: a three-season cohort study in Italy.European journal of pediatrics · 2026Article
- Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants.Human vaccines & immunotherapeutics · 2025Article
- Respiratory syncytial virus positivity, seasonal trends and risk factors among children under five with acute respiratory infection in Western Democratic Republic of Congo, 2022-2023.BMC infectious diseases · 2025Article
- Respiratory virus circulation during pandemic: Why were some viruses still circulating?Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Review
- Article
- Risk factors for respiratory syncytial virus (RSV) infection in children under 5 years old with acute lower respiratory tract infection.Journal of thoracic disease · 2025Article
- Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025.MMWR. Morbidity and mortality weekly report · 2025Article
- Molecular epidemiological surveillance of respiratory syncytial virus infection in Myanmar from 2019 to 2023.Scientific reports · 2025Article
- Clinical manifestations, para-clinical features and outcome of Iranian adults with respiratory syncytial virus (RSV) infection: a report from hospitalized patients.BMC infectious diseases · 2025Article
- Six-year epidemiological dynamics of human respiratory syncytial virus infections in children in central China (2019-2024): pandemic suppression, 2023 resurgence, and immune debt effect.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Respiratory syncytial virus: challenges in diagnosis and impact on the elderly: Recommendations from a multidisciplinary panel.Human vaccines & immunotherapeutics · 2024Review
- Etiological analysis of acute respiratory infections in hospitalized children after the relaxation of COVID-19 non-pharmacological interventions in Quzhou, China.BMC infectious diseases · 2024Article
- Article
- Respiratory syncytial virus-associated pneumonia in primary care in Malawi.Journal of tropical pediatrics · 2024Article
- Risk Analysis of Respiratory Syncytial Virus Among Infants in the United States by Birth Month.Journal of the Pediatric Infectious Diseases Society · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seasonal epidemics of respiratory syncytial virus (RSV) is one of the leading causes of hospitalization and mortality among children. Preventive measures implemented to reduce the spread of SARS-CoV-2, including facemasks, stay-at-home orders, closure of schools and local-national borders, and hand hygiene, may have also prevented the transmission of RSV and influenza. However, with the easing of COVID-19 imposed restrictions, many regions are noticing a delayed RSV outbreak. Some of these regions have also noted an increase in severity of these delayed RSV outbreaks partly due to a lack of protective immunity in the community following a lack of exposure from the previous season. Lessons learned from the COVID-19 pandemic can be implemented for controlling RSV outbreaks, including: (1) measures to reduce the spread, (2) effective vaccine development, and (3) genomic surveillance tools and computational modeling to predict the timing and severity of RSV outbreaks. These measures can help reduce the severity and prepare the health care system to deal with future RSV outbreaks by appropriate and timely allocation of health care resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.